Barclays PLC Sage Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 127,789 shares of SAGE stock, worth $695,172. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,789

Previous 127,789 -0.0%

Holding current value

$695,172

Previous $923,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.02 - $13.08 $345,180 - $643,156	49,171 Added 62.54%	127,789 $923,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $7,448 - $12,601	704 Added 0.9%	78,618 $853,000
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $2.22 Million - $3.21 Million	-119,146 Reduced 60.46%	77,914 $1.46 Million
Q4 2023 Feb 15, 2024	SELL	$17.1 - $22.26 $159,936 - $208,197	-9,353 Reduced 4.53%	197,060 $4.27 Million
Q3 2023 Nov 07, 2023	BUY	$16.75 - $48.98 $1.05 Million - $3.06 Million	62,454 Added 43.38%	206,413 $4.25 Million
Q2 2023 Aug 03, 2023	SELL	$40.65 - $59.54 $126,136 - $184,752	-3,103 Reduced 2.11%	143,959 $6.77 Million
Q1 2023 May 04, 2023	BUY	$37.27 - $46.57 $1.89 Million - $2.36 Million	50,739 Added 52.68%	147,062 $6.17 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $297,624 - $403,087	-9,243 Reduced 8.76%	96,323 $3.67 Million
Q3 2022 Nov 03, 2022	BUY	$32.28 - $43.27 $3.2 Million - $4.29 Million	99,159 Added 1547.67%	105,566 $4.13 Million
Q2 2022 Aug 12, 2022	SELL	$27.52 - $37.99 $850,092 - $1.17 Million	-30,890 Reduced 82.82%	6,407 $206,000
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $800,149 - $1.19 Million	-26,055 Reduced 41.13%	37,297 $1.24 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $477,518 - $607,012	12,885 Added 25.53%	63,352 $2.7 Million
Q3 2021 Nov 09, 2021	BUY	$40.26 - $57.37 $892,040 - $1.27 Million	22,157 Added 78.27%	50,467 $2.24 Million
Q2 2021 Aug 13, 2021	SELL	$54.88 - $79.29 $1.99 Million - $2.87 Million	-36,222 Reduced 56.13%	28,310 $1.61 Million
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $4.28 Million - $5.86 Million	60,523 Added 1509.68%	64,532 $4.83 Million
Q4 2020 Feb 11, 2021	BUY	$58.41 - $89.06 $11,857 - $18,079	203 Added 5.33%	4,009 $347,000
Q3 2020 Nov 12, 2020	SELL	$41.13 - $62.45 $577,876 - $877,422	-14,050 Reduced 78.69%	3,806 $233,000
Q2 2020 Aug 12, 2020	SELL	$25.95 - $43.15 $2.05 Million - $3.41 Million	-79,068 Reduced 81.58%	17,856 $741,000
Q1 2020 May 13, 2020	SELL	$26.15 - $77.24 $300,594 - $887,873	-11,495 Reduced 10.6%	96,924 $2.78 Million
Q4 2019 Feb 10, 2020	BUY	$60.18 - $154.77 $4.36 Million - $11.2 Million	72,410 Added 201.09%	108,419 $7.83 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $2.4 Million - $3.24 Million	17,075 Added 90.18%	36,009 $5.05 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $2.66 Million - $3.09 Million	16,856 Added 811.16%	18,934 $3.47 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $3.8 Million - $6.96 Million	-42,510 Reduced 95.34%	2,078 $330,000
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $2.62 Million - $4.47 Million	31,973 Added 253.45%	44,588 $4.27 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $6.75 Million - $8.26 Million	-48,862 Reduced 79.48%	12,615 $1.78 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $7.23 Million - $9.05 Million	51,480 Added 514.95%	61,477 $9.62 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $29.6 Million - $37.4 Million	-194,333 Reduced 95.11%	9,997 $1.61 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $10.4 Million - $28.8 Million	172,037 Added 532.74%	204,330 $33.7 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $1.98 Million - $2.86 Million	32,293	32,293 $2.01 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account